Europe, the CHMP recommended approval of Acomplia
The Advisory Panel (CHMP) (European Medicines Agency) gave a positive opinion for approval of Rimonabant (Acomplia) in the treatment of obesity (BMI greater than or equal to 30) or overweight (BMI greater than 27) with associated risk factors such as diabetes and dyslipidemia. Sanofi-Aventis said that rimonabant not only reduces body weight, but improves also glycosylated hemoglobin (HbA1c), raises levels of HDL cholesterol and reduces triglycerides. In the U.S., the FDA sent to Sanofi-Aventis an approvable letter for Acomplia, which includes additional documentation prior to approval.
Source: Sanofi-Aventis, 2006
0 comments:
Post a Comment